Valour Enters Swiss Market with HBAR and ICP Staking ETP Listings on SIX Swiss Exchange
Valour Launches First Products on SIX Swiss Exchange: Valour has officially entered the Swiss market with the listing of two staking ETPs—1Valour Hedera (HBAR)... Read more.
Pye-Barker Fire & Safety Acquires Idaho Fire Sprinkler Leader Accurate Fire Protection Solutions
ATLANTA, July 17, 2025 /PRNewswire/ — Pye-Barker Fire & Safety — the largest fully integrated and full-service fire protection, life safety and... Read more.
Why Outdated Tech is Costing Nonprofits More Than They Realize
Legacy donor systems are silently undermining efficiency, donor retention, and long-term impact—while AI-powered, consolidated data platforms are emerging... Read more.
Kyruus Health Expands Reach to Integrate with Bing and Other AI Experiences Consumers Use to Find Care
BOSTON, July 17, 2025 /PRNewswire/ — Building on the successful launch of Reach in October 2024, Kyruus Health, the leading care access platform, today announced... Read more.
BingX Rolls Out VoteX: Community-Driven Futures Listing Initiative
PANAMA CITY, July 17, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, today announced the launch of VoteX, an interactive... Read more.
General Glen D. VanHerck Joins C Speed Board of Directors
Former NORAD and USNORTHCOM Commander Brings Strategic Defense Insight to Innovative Radar Company SYRACUSE, N.Y., July 17, 2025 /PRNewswire/ — C Speed,... Read more.
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
Company aims for technology advancement and platform expansion with Korea’s first influenza vaccine using an adjuvant Interim results from the Phase 1/2 trial... Read more.
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
MINNEAPOLIS, July 17, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on... Read more.
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression... Read more.
Deus X Capital Partners with Soter for Innovative Digital Asset Risk Coverage
Soter’s Hybrid BTC/USD-Denominated Insurance Offers True Asset-Aligned Protection for Virtual Asset Service Providers ABU DHABI, UAE, July 17, 2025 /PRNewswire/... Read more.